VEN elderly CLL 2019 final BJH BJH-2019-01315 R2.pdf (283.28 kB)
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia
journal contribution
posted on 2020-03-20, 11:22 authored by Harriet S Walter, TA Eyre, LE Roeker, C Fox, S Gohill, R Walewska, F Forconi, A Arumainathan, D Brander, J Allan, S Schuster, B Hill, F Lansigan, B Cheson, N Lamanna, C Coombs, P Barr, A Skarbnik, M Shadman, C Ujjani, L Pearson, J Pagel, R Jacobs, A Mato, A BroomElderly chronic lymphocytic leukaemia (CLL) patients treated outside of trials have notably greater toxicity with the Bruton's tyrosine kinase inhibitor ibrutinib compared to younger patients. It is not known whether the same holds true for the B‐cell lymphoma 2 inhibitor venetoclax. We provide a comprehensive analysis of key safety measures and efficacy in 342 patients comparing age categories ≥75 and <75 years treated in the relapsed, refractory non‐trial setting. We demonstrate that venetoclax has equivalent efficacy and safety in relapsed/refractory CLL patients who are elderly, the majority of whom are previous ibrutinib‐exposed and therefore may otherwise have few clear therapeutic options.
Funding
Oxford NIHR Biomedical Research Centre
History
Citation
British Journal of Haematology, 2019, 188, 6, pp. 918-923Author affiliation
Cancer Research CentreVersion
- AM (Accepted Manuscript)
Published in
British Journal of HaematologyVolume
188Issue
6Pagination
918-923Publisher
Wileyissn
0007-1048eissn
1365-2141Acceptance date
2019-09-09Copyright date
2019Publisher DOI
Publisher version
https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.16271Language
enAdministrator link
Usage metrics
Categories
No categories selectedLicence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC